Inventor
MOULDER KEVIN
GB23 patents
⚠️ This page may combine multiple inventors who share the name “MOULDER KEVIN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
TUSK THERAPEUTICS LTD
12 patentsUS10752691B2Aug 25, 2020
Anti-CD25 antibody agents
TUSK THERAPEUTICS LTD12 citations93
US10745485B2Aug 18, 2020
Anti-CD25 antibody agents
TUSK THERAPEUTICS LTD11 citations93
US10738125B2Aug 11, 2020
Anti-CD25 antibody agents
TUSK THERAPEUTICS LTD11 citations93
US11787866B2Oct 17, 2023
Anti-CD25 antibody agents
TUSK THERAPEUTICS LTD1 citations72
US11697688B2Jul 11, 2023
Anti-CD25 for tumour specific cell depletion
TUSK THERAPEUTICS LTD1 citations72
US11814434B2Nov 14, 2023
Anti-CD25 for tumour specific cell depletion
TUSK THERAPEUTICS LTD0 citations62
US11802160B2Oct 31, 2023
Anti-CD25 antibody agents
TUSK THERAPEUTICS LTD0 citations62
US11802161B2Oct 31, 2023
Anti-CD25 for tumour specific cell depletion
TUSK THERAPEUTICS LTD0 citations62
US11919960B2Mar 5, 2024
Anti-CD25 antibody agents
TUSK THERAPEUTICS LTD0 citations61
US11873341B2Jan 16, 2024
Anti-CD25 for tumour specific cell depletion
TUSK THERAPEUTICS LTD0 citations61
US11851494B2Dec 26, 2023
Anti-CD25 for tumour specific cell depletion
TUSK THERAPEUTICS LTD0 citations61
US11879014B2Jan 23, 2024
Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
TUSK THERAPEUTICS LTD0 citations56
Black Belt Therapeutics Ltd
7 patentsUS12343394B2Jul 1, 2025
CD38 modulating antibody agents
Black Belt Therapeutics Ltd0 citations59
US12304964B2May 20, 2025
CD38 modulating antibody
Black Belt Therapeutics Ltd0 citations59
US12162949B2Dec 10, 2024
CD38 antibody
Black Belt Therapeutics Ltd0 citations59
US12161717B2Dec 10, 2024
CD38 modulating antibody agents
Black Belt Therapeutics Ltd0 citations59
US11780930B2Oct 10, 2023
CD38 modulating antibody
Black Belt Therapeutics Ltd0 citations59
US11542338B2Jan 3, 2023
CD38 modulating antibody
Black Belt Therapeutics Ltd1 citations59
US11236173B2Feb 1, 2022
CD38 antibody
Black Belt Therapeutics Ltd1 citations59
DOMANTIS LTD
3 patentsUS7563443B2Jul 21, 2009
Monovalent anti-CD40L antibody polypeptides and compositions thereof
DOMANTIS LTD42 citations95
US7927596B2Apr 19, 2011
Methods of antagonizing binding of CD40 to CD40L with CD40L-specific monovalent polypeptides
DOMANTIS LTD5 citations72
US7829096B2Nov 9, 2010
CD40L-specific monovalent polypeptides
DOMANTIS LTD4 citations72